{"commentary":{"count":56,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":24,"podcast":20,"youtube":12},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03811002\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT03811002","nct_id":"NCT03811002","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03811002. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1. Cycles repeat every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo 3D-CRT or IMRT BID for approximately 3 weeks or QD for approximately 6-7 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo blood specimen collection throughout the trial.","label":"Arm I (chemotherapy, radiation therapy)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive treatment as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 or 2 of each chemotherapy cycle. Cycles repeat every 3 weeks for 17 cycles (1 year) in the absence of disease progression or unacceptable toxicity. Patients undergo blood specimen collection throughout the trial.","label":"Arm II (chemotherapy, radiation therapy, atezolizumab)","type":"EXPERIMENTAL"}],"collaborators":["NRG Oncology"],"completion_date":{"date":"2029-02-21","type":"ESTIMATED"},"conditions":["Limited Stage Lung Small Cell Carcinoma","Stage I Lung Cancer AJCC v8","Stage II Lung Cancer AJCC v8","Stage III Lung Cancer AJCC v8"],"enrollment":{"count":544,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"3-Dimensional Conformal Radiation Therapy","type":"RADIATION"},{"name":"Atezolizumab","type":"DRUG"},{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Carboplatin","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Etoposide","type":"DRUG"},{"name":"Intensity-Modulated Radiation Therapy","type":"RADIATION"},{"name":"Quality-of-Life Assessment","type":"OTHER"},{"name":"Questionnaire Administration","type":"OTHER"}],"last_update":"2026-08-27","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-04-21","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival","timeFrame":"Randomization to date of death due or last follow-up. Median follow-up at the time of analysis was 23.8 months."}],"references":[{"citation":"Movsas B, Hu C, Higgins KA, Ross HJ, Jabbour SK, Kozono D, Owonikoko TK, Xiao C, Shoji T, Faller BA, Mohindra P, Dib EG, Brownstein J, Chun SG, Kuzma CS, Kotecha R, Onitilo A, Mulford D, Paulus R, Bradley JD, Bruner DW. Comprehensive Patient-Reported Outcomes from NRG Oncology/Alliance LU005: A Randomized Trial of Chemoradiation With or Without Atezolizumab in Limited-Stage SCLC. J Thorac Oncol. 2026 Jul 30:104117. doi: 10.1016/j.jtho.2026.104117. Online ahead of print.","pmid":"42532339","type":"DERIVED"},{"citation":"Higgins KA, Hu C, Ross HJ, Jabbour SK, Kozono DE, Owonikoko TK, Ritter TA, Williams TM, Welsh J, Simko JP, Movsas B, Xiao C, Kaira K, Gupta AK, Mohindra P, Dib EG, Brownstein J, Chun S, Kuzma CS, Kotecha R, Onitilo AA, Chen Y, Stinchcombe TE, Wang X, Paulus R, Bradley JD. Chemoradiation +/- Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005. J Clin Oncol. 2026 Mar 10;44(8):630-640. doi: 10.1200/JCO-25-01569. Epub 2026 Jan 13.","pmid":"41529214","type":"DERIVED"},{"citation":"Higgins KA, Thomas A, Soto N, Paulus R, George TJ, Julian TB, Hartson Stine S, Markham MJ, Werner-Wasik M. Creating and Implementing a Principal Investigator Tool Kit for Enhancing Accrual to Late Phase Clinical Trials: Development and Usability Study. JMIR Cancer. 2022 Aug 25;8(3):e38514. doi: 10.2196/38514.","pmid":"36006678","type":"DERIVED"}],"start_date":{"date":"2019-07-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)","url":"https://clinicaltrials.gov/study/NCT03811002"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03811002"}